Clinical Trial Update: Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

View source ↗

Summary

A completed clinical trial evaluating post-marketing use of CT-P13 (infliximab) for standard care in patients with rheumatoid diseases who are biologic-naïve or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• CT-P13 (infliximab) (infliximab)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Diseases, Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2020-01-13